Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756409 | 1.00 | TDP1 (0.46) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22256341 | 1.00 | TDP1 (0.46) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL21082300 | 1.00 | TDP1 (0.46) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL21521446 | 0.98 | TDP1 (0.47) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL19451348 | 0.92 | TDP1 (0.47) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL18886420 | 0.92 | TDP1 (0.47) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL24922459 | 0.92 | TDP1 (0.40) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL26150015 | 0.91 | TDP1 (0.47) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL14742521 | 0.90 | TDP1 (0.49) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL28989738 | 0.89 | TDP1 (0.46) | TDP1MEN1KMT2AGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3947417-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201743-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | TDP1 4188/4885MEN1 1142/4885KMT2A 4517/4885 |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, MYD88, CD47 | TDP1 2941/4885MEN1 2217/4885KMT2A 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.